Market Place
Sourcing Support
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept
17 Apr 2023 //
PR NEWSWIRE
Lilly inks licensing deal for cancer therapy with Australian biotech Telix
12 Apr 2022 //
SEEKING ALPHA
Lilly inks licensing deal for cancer therapy with Australian biotech Telix
11 Apr 2022 //
SEEKING ALPHA
Keytruda is First to Add Indications Under TGA’s Provisional Approval Pathway
18 Jul 2019 //
RAPS
Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
11 Jul 2019 //
FIERCE PHARMA
Suffering a series of setbacks, Eli Lilly’s oncology executes 2 of its top drugs
30 Apr 2019 //
ENDPTS
Eli Lilly to Pull Cancer Drug From Market After Failed Study
26 Apr 2019 //
BIOPHARMADIVE
Eli Lilly aims to keep current Lartruvo patients as drug exits world stage
25 Apr 2019 //
FIERCE PHARMA
Eli Lilly backs U.S. proposal on drug rebates to lower costs
07 Feb 2019 //
REUTERS
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
04 Feb 2019 //
HEALTH CANADA
EMA says Lilly’s Lartruvo should not be prescribed
24 Jan 2019 //
PMLIVE
No new patients should start treatment with Lartruvo
23 Jan 2019 //
EMA
No New Patients Should Start Treatment With Lilly’s Lartruvo
23 Jan 2019 //
RAPS
Lilly stops promoting cancer drug after shock trial failure
19 Jan 2019 //
PHARMAPHORUM
Apexigen Announces Clinical Collaboration Phase 2 Trial For APX005M In Sarcoma
20 Dec 2018 //
PR NEWSWIRE
Eli Lilly`s Biological Lartruvo (Olaratumab) Receives Approval in US
14 Aug 2018 //
FDA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.